Collectively, our data demonstrates that SLC22A18 promoter methylation contributes to the downregulation of SLC22A18 in gliomas and reduced SLC22A18 expression plays a role in the molecular pathogenesis of glioma, as SLC22A18 overexpression can effectively inhibit U251 glioma cell growth and adhesion in vitro and tumor growth in vivo. The gene discussed is SLC67A1; the disease is neoplasm.